Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q2 2019 · 10-Q
Revenue$11.02M$11.02M−0.5% vs Q2 2018 Net Income-$1.26M-$1.26MN/M vs Q2 2018 EPS Diluted-$0.67-$0.67N/M vs Q2 2018 Gross Profit$2,382,175−0.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Operating Cash Flowderived-$490,022N/M Margins · derivedGross margin21.6%+0.1 pt vs Q2 2018
Operating margin-13.4%−4.9 pt vs Q2 2018
Net margin-11.4%−0.0 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 14, 2019 · 45 d after period end